We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Analysis of Process Related Impurities in Cell & Gene Therapy Products by SWATH LC-MS


Analysis of Process Related Impurities in Cell & Gene Therapy Products by SWATH LC-MS

Who's speaking at this Webinar?

Ejvind Mortz, PhD.
Co-Founder & COO, Alphalyse

The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple organisms. A commercial host cell protein (HCP)-ELISA kit is often not available for the cell line or is not suitable for the specific process due to a low HCP coverage. Development of a process-specific ELISA can be unfeasible as the product often requires a short development time.

HCP analysis by SWATH LC-MS is overcoming several of these challenges and has multiple advantages:

  • Enables quantification of the total HCP amount in ng/ml drug substance
  • Identifies and quantifies each individual HCP
  • Provides identification and quantification of each individual viral protein
  • Identification of other process related impurities, such as benzonase, and bovine serum albumin.

By attending this webinar, you will learn:

  • Regulatory guidelines for process-related impurities in cell & gene therapy products
  • How to identify and quantify protein impurities by SWATH LC-MS for process consistency and product purity
  • Case examples of immunotherapy products based on oncolytic viruses in human cell lines


Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free